INTRODUCTION
Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer mortality worldwide (Torre et al., 2015) . It is a highly heterogeneous disease presenting a range of histopathological appearances and molecular signatures. The Lauren classification has traditionally categorized GCs into two major histological subtypes: intestinal type GC (IGC) and diffuse type GC (DGC) (Lauren, 1965) . IGC is characterized by a glandular or papillary structure with various differentiation degrees and frequently arises from intestinal metaplasia (IM) in association with Helicobacter pylori infection (Bosman et al., 2010) . DGC exhibits a discohesive tissue architecture and typically arises from a non-IM background. Around 10%-15% of GCs consist of carcinoma with mixed intestinal and diffuse features, referred to as the Mixed type, or other rare histological subtypes, such as hepatoid adenocarcinoma. Recently, deep sequencing analyses have stratified GCs into four genetic subtypes: Epstein-Barr virus (EBV)-positive, microsatellite instability (MSI), chromosomal instability (CIN), and genomically stable (GS) GCs (Cancer Genome Atlas Research Network, 2014) . Most intestinal and diffuse histological subtypes of GCs fall into the CIN and GS subtypes, respectively, indicating the robust correlation between genetic and histological classifications. Genetic analyses additionally identified recurrent genetic mutations in each subtype, for instance, frequent CDH1 and RHOA mutations in the GS subtype (Cancer Genome Atlas Research Network, 2014; Kakiuchi et al., 2014; Wang et al., 2014) . Despite these clear views of the genetic diversity across human GCs, the mechanistic connection between their genotypes and phenotypes has largely remained unclear, owing to a lack of functionally tractable platforms for human GC research.
To date, numerous genetically engineered mice have been generated to model spontaneous gastric tumorigenesis in vivo (Hayakawa et al., 2013; Poh et al., 2016) . Though mouse models have provided important insights into GC pathogenesis, their genetic backgrounds are mostly irrelevant to the human GC genetics. Moreover, tumorigenesis in these genetic models requires long latency, suggesting that multiple genetic alterations are essential for the development of full-blown cancers. GC cell lines have alternatively served as accessible pre-clinical models for GC drug development. Nonetheless, their low establishment efficiency and biological distinction from clinical cancers often biases the interpretation of their phenotypes. Patient-derived xenograft models offer complementary means for mitigating these challenges, but several obstacles, such as the modest establishment efficiency, low throughput, and genetic intractability, remain open issues (Wang et al., 2017) .
Recently, the organoid technology has emerged as an option for culturing patient-derived GCs, which allows long-term expansion of human gastric epithelium using a specific combination of stem cell ''niche factors'' that are essential for the self-renewal of gastric epithelial stem cells-namely, Wnt-3A and R-spondin (Wnt signal activators), EGF, FGF10, Noggin (a BMP inhibitor), and A83-01 (a TGF-b inhibitor) (Barker et al., 2010; Bartfeld et al., 2015) . Based on this technology, we generated a collection of 37 patient-derived GC organoids that largely covered the histological and molecular diversity of clinical GCs. Patient-derived GC organoids displayed varying niche factor dependencies defined by genetic and non-genetic mechanisms. Integrated genotype-phenotype analyses using patient-derived and CRISPRCas9-engineered gastric organoids directly illustrated how genetic alterations translate into cancer phenotypes, such as histopathological transformation and R-spondin independency.
RESULTS

Establishment and Enrichment of GC Organoids
Using the culture condition modified for gastric tissue, we sought to establish GC organoids from clinical GC samples (Figure 1A) . During preliminary studies, we frequently experienced the overgrowth of normal gastric organoids from GC specimens, which hampered the establishment of slow-growing GC organoids. To circumvent the unintended overgrowth of normal organoids, we harnessed recurrently dysregulated signals in human GCs: the TP53, RHO, TGF-b, and RAS-PI3K pathways (Cancer Genome Atlas Research Network, 2014) . To eliminate potentially existing normal organoids and enrich GC organoids, we first used Nutlin-3, an MDM2 inhibitor, to select TP53 mutant GC organoids . Sequencing analyses confirmed the existence of TP53 mutations in Nutlin-3 resistant organoids (B) Molecular (type/CIMP) and histological (pathology/morphology) subtypes, niche factor dependencies, genetic alterations and copy number statuses of the GTOL. Frequency of each genetic alteration in the GTOL and the TCGA report, and the overall copy number status across the GTOL is shown on the right. (C) PCA plots for the transcriptome (left) and methylome (right). Each organoid is colored according to its type in (B) . Normal organoids; light gray. CIMP statuses are indicated with dotted circles (right). (D) Hierarchical clustering based on the methylation levels of top 1000 genes with highest variances in GC organoids. Average M-values in normal gastric organoids are shown on the left. Type and CIMP status colors are the same as those used in (B) . See also Figure S1 and S2. (Figure 1B) . Second, because ROCK inhibition is essential for the recovery of individualized organoid cells, we challenged them in a ROCK inhibitor (Y-27632)-free medium to enrich RHO-dysregulated GCs. Third, we treated the organoids with TGF-b in the absence of A83-01 to select GC organoids insensitive to TGF-b stimulation. Last, we used an EGF and FGF10 (EF)-removed culture condition to select organoids with ligandindependent receptor tyrosine kinase (RTK) signal activation (Figure 1B) . These positive selections allowed for efficient generation of GC organoids from various lesions (primary tumors, metastases, and carcinomatous ascites) and histologic types, including poorly differentiated adenocarcinoma, signet ring cell carcinoma, and hepatoid adenocarcinoma (Table S1 ). The gross organoid establishment efficiencies before and after the protocol standardization were 54.7% (23 lines from 42 specimens) and 74.6% (44 lines from 59 specimens), respectively. Non-neoplastic gastric organoids were established in parallel from the same patients. We also established six normal gastric organoids from Helicobacter pylori-free donors and one IM organoid from an endoscopically diagnosed IM lesion. All established organoids were confirmed for their propagation persisting for at least 3 months and stored in liquid nitrogen for on-demand usage as a gastric tumor organoid library (GTOL).
Genomic Characterization of GC Organoids
As described above, primary GC organoid culture often appears as a mosaic of GC and normal organoids, and their tumor-origin should thus be evaluated closely. Accordingly, we performed whole-exome sequencing (WES) and copy number and MSI analyses on selected organoids and defined their cancer origin by the following criteria: the presence of recurrent driver gene mutations, the existence of aneuploidy, or the sign of solid morphology with a loss of apicobasal polarity. Among the 67 lines of organoids derived from GC tissues, 46 lines were subjected to further WES analysis, of which 37 lines were judged as GC organoids. The remaining nine lines did not fulfill any of above criteria and were considered non-cancer organoids that had overgrown from GC tissues, hereafter called normal-like (NL) organoids (Figure 1B) . Of note, all GC organoids were either insensitive to Nutlin-3/TGF-b treatment or independent of Y-27632, corroborating the stringency of the aforementioned niche-based selection steps. The establishment rate of GC organoids did not differ among histopathological subtypes.
We subsequently determined the genetic subtypes of the 36 established GC organoids based on the recent comprehensive molecular classification. We failed to derive EBV-positive GC organoids due to their rarity in our cohort. MSI and copy number analyses identified 7, 25, and 4 organoids as MSI-, CIN-, and GS-GCs, respectively. The mutation frequencies of the representative genes were comparable to those in previous reports except for the incidences of CDH1, PIK3CA, and ARID1A mutations, which may reflect different composition of molecular subtypes in our cohort (Figure 1B) . Three of the 25 CIN-GC organoids were subjected to secondary WES after additional 3-5 passages. Comparison with the initial WES data confirmed their genetic stability during the culture period ( Figure S1A ). Copy number analyses identified recurrent gene amplifications and losses in a similar fashion as the previous report (Cancer Genome Atlas Research Network, 2014) ( Figures 1B and S1B ). The amplifications of cyclin and cyclin-dependent kinase genes (CCNE1, CCND1, and CDK6) were mutually exclusive to the homozygous deletions of cell cycle inhibitors (CDKN2A and CDKN2B) in GC organoids (Figure S1C) .
Consistent with the original report, all four GS-GC organoids derived from DGCs showed minimal chromosomal alterations. The pure tumor composition of organoids unveiled diverse CDH1 gene alterations in GS-GCs (Figures S1D-S1F ). GC13 carried biallelic mutations in the cadherin domain. GC16 had a focal deletion of one allele and a mutation in the consensus splicing sequence in the remaining allele, which had initially been overlooked by the conventional mutation identifier in our pipeline. GC08 showed a single missense mutation accompanied by a copy-neutral loss of heterozygosity (CN-LOH) of the genomic region spanning CDH1. Of note, GC08 harbored RNF43 and TGFBR2 mutations, both of which involved CN-LOH (Figure S1G ). These observations indicated that GS-GCs could accumulate functional genetic mutations through CN-LOH without any evident sign of aneuploidy. Indeed, copy number analysis identified an additional CN-LOH in the chromosome 20 of GC16 (Figure S1G) . Although such precise genetic analyses of GS-GCs have been challenging owing to their low tumor purity, organoid-based cancer cell expansion enabled detection and characterization of minor genetic events occurring in GS-GC tissues.
Transcriptomic Characterization of GC Organoids
We next investigated gene expression signatures of the GTOL using microarray analysis. Principal component analysis (PCA) largely separated GC organoids from normal and NL organoids, reinforcing the specificity of the criteria we used for diagnosing tumor origin ( Figure 1C) . Interestingly, the IM-derived organoid line and three NL organoids exhibited distinct gene expression patterns from those of normal gastric organoids. This population was characterized by the upregulation of the IM marker genes CDX1, CDX2, VIL1, FABP1, and CDH17 and the downregulation of the gastric marker genes SOX2, GKN1, GKN2, and KCNE2 (Melé et al., 2015) (Figure S2A) . We confirmed the presence of IM in their original stomachs and thus included these NL organoids in IM organoids. IM organoids were morphologically indiscernible from normal gastric organoids, while immunostaining for CDX2 depicted the metaplastic change of IM organoids (Figure S2B) .
We next performed methylation microarray analysis to gain insights into the diversified gene expression signatures of the GTOL. PCA clearly depicted normal, IM, and two subgroups within GC organoids, suggesting the presence of distinct epigenetic modifications in each population (Figure 1C) . Different methylation patterns between IM and normal gastric organoids were consistent with a recent report on gastric tissues (Huang et al., 2018) . The two methylation subtypes within GC organoids showed different methylation levels of gastric CpG island methylator phenotype (CIMP) genes (Wang et al., 2014) , and we thus referred to these populations as CIMP + and CIMP À GCs ( Figure 1D ). Previous studies have associated most MSI + GCs with the CIMP, particularly with MLH1 hypermethylation, which directs them toward the mutation-prone phenotype (Cancer Genome Atlas Research Network, 2014). Consistently, 5 of the 7 MSI-GC organoids showed CIMP + and MLH1 hypermethylation, suggesting their persistent methylation patterns during culture. Of note, CIMP + and CIMP À GC organoids exhibited differing gene expression patterns ( Figure S2C ). The CIMP + GC-specific gene expression pattern extended to CIMP + colon tumor organoids when transcriptome data of gastric and colon tumor organoids were integrated ( Figure S2D ). These results highlight the common tumorigenic role of the CIMP in the gastrointestinal epithelium, consistent with the recent comprehensive molecular analysis on gastrointestinal cancers (Liu et al., 2018) . The methylation analysis also assigned all four GS-GC organoids as CIMP + GCs. Unlike MSI-GC organoids, these GS-GC organoids were devoid of MLH1 hypermethylation in line with their genetic stability. Although most GS-GCs have previously been categorized into the CIMP À subtype (Cancer Genome Atlas
Research Network, 2014), massive infiltration of fibroblasts in GS-GC tissues might have biased their methylome data. In contrast, the organoid culture platform allowed the accurate determination of gene expression and DNA methylation patterns of GCs regardless of the tumor purity in original specimens.
Morphological Characterization of GC Organoids
Established GC organoids exhibited various morphological appearances reminiscent of the diverse histological subtypes in clinical GCs. To connect the histological subtypes and the organoid structures, we classified GC organoids into ''solid'', ''glandular'', and ''mixed'' subtypes according to their morphological appearance (Figures 2A and S3 ). The solid subtype typically derived from DGCs and showed amorphous solid configurations with a loss of apicobasal polarity, while the glandular subtype was enriched with IGCs and typically formed single lumens lined by a single cellular layer. Analogous to the mixed histological GC subtype, we categorized cases comprising both solid and glandular populations into the mixed subtype. Our morphological subtypes largely matched their original histological subtypes, albeit with some inconsistencies ( Figure 2B ). To investigate the stability of morphological phenotypes, we manually isolated solid and glandular organoids from parental mixed subtypes. These subcloned organoids retained their structures during culture, supporting their morphological stability ( Figure S3 ). Of note, WES of mixed and glandular subclones from a mixed organoid line revealed a loss of genetic heterogeneity after the morphology-based subcloning, suggesting that the morphological diversification accrued along with the genetic heterogeneity formation ( Figure S1A ).
Genetic Modeling of Morphological Transformation in DGCs
To gain insights into the mechanism of the morphological transformation during GC development, we determined the genetic mutations responsible for the solid subtype in the GTOL. WES revealed recurrent CDH1 mutations in solid GC organoids regardless of molecular subtypes, highlighting the role of CDH1 mutations in specifying DGC-like organoid structures (Figure 2B ). Two CDH1 mutant DGC organoids simultaneously harbored RHOA mutations (one with G62E and the other with L22I). As was reported previously (Cancer Genome Atlas Research Network, 2014; Kakiuchi et al., 2014; Wang et al., 2014) , both RHOA mutations in solid GC organoids were heterozygous and were found at recurrently mutated positions. To determine the functional effects of the RHOA mutations, we turned to a cell-line-based assay. An RHOA-fluorescence resonance energy transfer biosensor assay (Bindels et al., 2017) illustrated decreased affinity of RHOA G62E to the consensus RhoA-binding domain, which was suggestive of loss of function ( Figures S4A and S4B ).
To learn the phenotypic impact of CDH1 and RHOA mutations in organoids, we next performed knockout (KO) of CDH1 and/or RHOA genes in normal gastric organoids using CRISPR-Cas9 ( Figures 2C and 2D ). Both CDH1 and RHOA single-KO organoids showed enhanced recovery from single cells without a ROCK inhibitor, consistent with their altered adhesion signaling pathway ( Figure S4C ). Nonetheless, without a ROCK inhibitor during passage, CDH1 KO organoids diminished over time, whereas CDH1/RHOA double-KO (DKO) organoids vigorously propagated, suggesting that CDH1 loss alone was insufficient to abolish RHOA-ROCK-induced cell death induced by anoikis ( Figure S4D ). Figure 2F , Video S1). In contrast to the response in CDH1 KO normal gastric organoids, ROCK inhibitor treatment did not alter the solid structures of CDH1 mutant DGC organoids (Figure 2G) , underscoring the complex mechanisms regulating the morphological transformation.
CTNNA1 is an essential scaffolding molecule for adherens junctions that bridges the CDH1-CTNNB complex and the cytoskeleton (Takeichi, 2014) . We noted that CTNNA1 expression was lost in CDH1 KO organoids, whereas it reappeared after ROCK inhibitor treatment, suggesting the restoration of adherens junction during morphological reversion ( Figure S4H ). To determine the role of adherens junction in morphological transformation, we next knocked out CTNNA1 in normal gastric organoids. CTNNA1 is the only a catenin gene expressed in gastric organoids, and deletion of CTNNA2 or CTNNA3 did not induce morphological alteration (data not shown). In contrast, CTNNA1 KO organoids recapitulated the solid structure of DGCs. Strikingly, the solid morphology of CTNNA1 KO organoids was not reversed by ROCK inhibitor treatment, indicating that the disruption of adherens junctions was responsible for the solid structure phenotype ( Figure 2H ). Although somatic CTNNA1 mutations are rather rare in sporadic GCs, germline CTNNA1 mutations have been linked to the predisposition to familial DGC (Majewski et al., 2013 ). These data demonstrate that CDH1 mutations destabilize the intercellular integrity of the glandular structure, but additional molecular defects are required to reinforce the morphological transformation in DGCs. Collectively, human GC modeling by genetic engineering of human gastric organoids provided insights into the histopathological transformation during human gastric tumorigenesis.
EGF and FGF Niche-Dependent Growth Capacity in GC Organoids
To further investigate the genotype-phenotype correlations in GC, we next set our focus on the relationship between niche factor dependencies and genetic mutations ( Figure 3A ). GC organoids with a single ERBB3 or PTEN mutation failed to grow in the absence of EF, suggesting that these mutations alone were insufficient for the acquisition of EF independency. One KRAS-mutant GC organoid (GC13) showed EF dependency despite the phosphorylation of downstream ERK in the absence of EF ( Figures 3A-3C ). Of note, KRAS G12V gastric organoids generated by CRISPR-Cas9-mediated mutation knockin could grow in an EF-free medium ( Figure S5A ), suggesting that GC13 organoids had negated the oncogenic impact of the KRAS mutation through an unknown mechanism.
In agreement with the preference for ERBB amplification in GCs, GC organoids with ERBB2 or ERBB3 amplification were invariably EF-independent. A pan-ERBB receptor kinase inhibitor (Ei) treatment abrogated the proliferation of four out of five ERBB-amplified organoids, indicating their cell-autonomous receptor hyperactivation ( Figure 3B ). The growth-inhibitory effect of Ei on gastric organoids was reversed by supplementation with another RTK ligand, HGF, excluding a toxic effect of Ei ( Figure S5B ). The auto-activation of downstream ERK in ERBB-amplified GC organoids was further confirmed by immunoassay ( Figure 3C ). Five GC organoids without genetic alterations in EGFR and FGFR signaling pathways were also independent of EF and sensitive to Ei. Because the cell-autonomous activation of EGFR family members is the only mechanism that can account for this phenotype, we reasoned that the gene expression of EGF-related molecules was altered in these organoids. Accordingly, transcriptome data showed upregulation of EREG (epiregulin), a ligand of EGFR, in three of five EF independent GC organoids ( Figure 3D ). Epiregulin substituted EF in normal gastric organoids (Figure S5B) , suggesting that self-secretion of epiregulin contributed to EF independency.
Eight GC organoids tolerated Ei treatment. Three lines harbored genetic amplifications or mutations in KRAS and PIK3CA, which were presumed to drive this phenotype. In addition, three lines had genetic amplification of FGFR2 or MET, which alternatively conferred Ei resistance on GC organoids (Figure 3A) . Importantly, MET-amplified GC organoids were sensitive to a MET inhibitor, crizotinib ( Figure 3E ). These results indicate that the gastric epithelium engage multiple RTKs to efficiently activate RAS-PI3K pathways. Of note, two Ei-resistant GC organoids were devoid of known genetic alterations that confer Ei resistance. Given the observations that niche-independent phenotypes are not necessarily determined a priori by genetic alterations in GCs, testing for Ei sensitivity in patientderived GC organoids may be instructive when considering the indications for the ERBB pathway-targeting therapy, which is currently the standard of care for patients with ERBB2-positive GCs.
BMP-and TGF-b-Resistant Phenotypes in GC Organoids
The requirement for TGF-b and BMP4 inhibition for gastric organoid culture suggests growth suppressive roles of these ligands. Conversely, TGF-b and BMP4 treatments did not affect the growth of GC organoids with TGFBR2 and SMAD4 mutations, respectively, indicating that these mutations confer resistance to TGF-b and BMP ligands ( Figures S5C-S5E ). In addition to these mutation-driven resistances, we noted that some GC organoids devoid of TGFBR2 and SMAD4 mutations also tolerated stimulation with TGF-b and BMP4 ( Figure S5C ). These results suggest that in human GCs, both genetic mutations and non-genetic mechanisms contribute to the tolerance against TGFb and BMP-rich conditions and subsequently to the selective growth advantage in such environments, as was the case in colorectal cancers .
Wnt Niche-Independent Growth Capacity in GC Organoids Wnt and R-spondin (WR) are indispensable for normal gastric epithelium organoids, but it remains unknown whether GCs acquire Wnt signal independency during their progression. In the GTOL, 16 GC organoids grew without exogenous Wnt-3A, of which 4 GC organoids were sensitive to a Porcupine inhibitor (Porcn-i; C59) (Figures 4A and 4B) . Porcupine is essential for active Wnt ligand production (Proffitt et al., 2013) and thus these 4 GC organoid lines were considered dependent on endogenous Wnt production. In contrast, the other 12 GC organoids tolerated Porcn-i treatment and were judged to be Wnt ligand independent. Among these, six expressed AXIN2, a Wnt target gene, Figure 4E ). Although we could not detect APC genetic alterations in the other two Wnt CA GC organoids, capillary-based immunoassay revealed APC protein loss ( Figure 4F ). These results demonstrate that GCs adopt diverse mechanisms to deactivate APC and acquire a Wnt CA phenotype. The other 6 Wnt ligand-independent GC organoids showed intact ligand-induced Wnt pathway activation (Figure 4D ), indicating that they were WR independent (WRi) despite the intact Wnt signaling. To characterize these WRi GC organoids, we next analyzed the transcriptomes of GC organoids. Hierarchical clustering identified a cluster of genes that were uniquely upregulated in WRi GC organoids, designated as the WRi genes (Figure 4G , Table S5 ). WRi genes included X-chromosome-linked cancer-testis genes, which exhibited extensive DNA demethylation. These results suggested the presence of epigenetic alterations that coaxed GCs toward the WRi phenotype. Of note, a previous report identified elevated expression and promoter demethylation of cancer-testis genes as a poor prognostic factor of GC (Honda et al., 2004 ). Furthermore, high expression level of WRi genes in GC was significantly associated with an unfavorable patient outcome in public GC transcriptome data ( Figure 4H ). These results collectively highlighted several mechanisms that render exogenous Wnt dispensable in GCsnamely, the self-secretion of Wnt, APC mutations, and epigenetic WRi regulation.
RNF43-Mediated R-spondin Niche Independency in GC Organoids
Among the 24 Wnt ligand-dependent GC organoids, 15 GC organoids exhibited a unique R-spondin independency (Ri) (Figures 5A-5C ). R-spondin binds to LGR4/5 and stabilizes the Wnt receptors, LRP and Frizzled; otherwise, these Wnt receptors are ubiquitinated by RNF43 and ZNRF3 (de Lau et al., 2011; Hao et al., 2012; Koo et al., 2012) . Thus, the Ri phenotype could be attributed to two possible scenarios: auto-secretion of R-spondin by gene fusion and deletions of RNF43 and ZNRF3. Because we did not detect an upregulation of R-spondin mRNAs in Ri GC organoids, the former mechanism was negated. The high frequency of RNF43 mutations in GCs, identified in 15% of all cases (Wang et al., 2014) , implied that the Ri phenotype might reflect defective RNF43. Consistently, RNF43 mutations were enriched in Ri GC organoids ( Figure 5A ). As previously observed in intestinal organoids (Koo et al., 2012) , RNF43 single-KO gastric organoids remained dependent on R-spondin, underscoring the redundant function of an RNF43 homolog, ZNRF3 (data not shown). Our detailed genetic analyses further revealed various patterns of RNF43 and ZNRF3 gene alterations in Ri GC organoids. These genetic aberrations included not only RZ double mutations ( Figure 5D ) but also homozygous deletions of RZ ( Figure 5E ) and a concomitant mRNA downregulation of RZ ( Figure 5F ). Methylation microarray revealed CpG island methylation of ZNRF3 in GC28.
Despite the importance of ZNRF3 loss for the Ri phenotype, two RNF43 mutant Ri organoids lacked ZNRF3 gene alterations ( Figure 5A ). These results prompted us to investigate whether single RNF43 mutations could offer the Ri phenotype. One of these RNF43 mutations (D300Y) was mapped onto its RING finger domain, suggesting a dominant-negative effect of this mutation (Figure 5G ). To substantiate this possibility, we generated doxycycline-inducible expression constructs for RNF43 D300Y and RNF43 WT (Figure 5H) . While the expression of RNF43 WT did not affect the dependency on R-spondin (data not shown), RNF43 D300Y expression conferred Ri on normal gastric organoids (Figure 5I ), demonstrating that a specific RNF43 mutation could alternatively induce Ri through a dominant-negative effect. One MSI-GC organoid harbored a heterozygous frameshift mutation in RNF43 at a recurrently mutated site in MSI-GCs (G659fs) but remained strictly dependent on R-spondin ( Figure 5B ). Given our previous observation that MSI colorectal cancer organoids with the same mutation were also dependent on R-spondin , this MSI-type RNF43 mutation alone was considered insufficient for the Ri phenotype.
Novel Genetic Mutations Rendering GC Organoids R-spondin Independent Of 15 Ri GC organoids, 10 were devoid of RNF43 alterations. To explore genetic mechanisms that confer Ri on RNF43-intact GC organoids, we conducted a phenotype-based mutation screening using the WES data of the GTOL. From recurrently mutated genes in WRd and Ri GC organoids and their combinations, an unbiased screening algorithm identified CDH1 mutations and CDH1/TP53 compound mutations as significantly enriched mutations in the Ri subtype versus the WRd subtype ( Figure 6A ). Consistently, seven of the 10 RNF43-intact Ri GC organoids harbored simultaneous CDH1 and TP53 mutations ( Figure 6B ). To investigate the causality between this genotype and the Ri phenotype, we generated CDH1 and TP53 singleor double-KO organoids from normal gastric organoids. Notably, either CDH1 or TP53 single-KO organoids remained dependent on R-spondin, whereas CDH1/TP53 (CT)-DKO organoids gained an Ri phenotype ( Figure 6C ). CT DKO organoids were still dependent on exogenous Wnt-3A, suggesting that these organoids required Wnt signal activation ( Figure 6D ). The Ri phenotype by CT loss was validated using another line of normal gastric organoids ( Figure S6A ). We also generated CT-DKO organoids from two human IM organoid lines and one colon organoid line. Although CT-DKO IM and colon organoids acquired Nutlin-3 resistance and a discohesive morphology, they failed to grow in the absence of R-spondin ( Figures 6C and S6A) . These results suggested that CT loss induces Ri uniquely during gastric tumorigenesis.
To further characterize the CT loss-mediated Ri-phenotype, we analyzed the transcriptomes of CT-engineered organoids. CDH1 single-KO in gastric organoids induced the expression of cell-cycle-inhibitor genes, including CDKN2A, CDKN1A, and CDKN2B, whereas this effect was not observed in CT-DKO gastric organoids. CT-DKO further showed higher expression of Wnt target genes as compared to normal and CDH1 KO gastric organoids ( Figure S6B ). This trend was also observed in the comparison between CT-DKO gastric and colon organoids (Figures S6B and S6C) . These results suggest that CT loss increased the sensitivity to Wnt ligands and that TP53 loss blocked the induction of cell cycle inhibitors by CDH1 loss. CT-DKO gastric organoids remained responsive to R-spondin in that they showed robust downregulation of Wnt target genes upon R-spondin withdrawal, indicating that CT loss confer an Ri phenotype despite the intact R-spondin-LGR4/5-RNF43/ ZNRF3 axis ( Figure S6D ). In accordance with this result, RNF43 mutant GC organoids constitutively expressed Frizzled receptors regardless of R-spondin stimulation, while R-spondin removal decreased the surface expression levels of Frizzled receptors in WRd and CT mutant GC organoids ( Figure 6E ). These results collectively indicate that CT mutant GC organoids gain a unique Ri phenotype through a mechanism distinct from that of RNF43/ZNRF3 mutations. Although the precise molecular mechanism remains to be determined, our results demonstrate that the organoid-based forward genetic approach enables the genetic interpretation of biological phenotypes of patientderived cancers.
In Vivo Testing of a Wnt-Targeting Therapy on Xenotransplanted Human GC Organoids To generate preclinical in vivo models of human GCs, we attempted to establish a xenotransplantation system using GFP-labeled patient-derived GC organoids. When transplanted into kidney subcapsules of immunodeficient mice, only a fraction of GC organoids formed visible tumors. The particularly poor engraftment efficiency of WR-dependent GC organoids suggested the scarcity of the WR niche. Based on this notion, we co-transplanted GC organoids with human intestinal organoid-derived fibroblasts (HIOFs) that were generated from human pluripotent stem cells and known to produce WR (Watson et al., 2014) (Figure 7A) . As we expected, co-transplantation with HIOFs significantly improved the engraftment efficiency of WR-dependent GC organoids ( Figure 7B ). Using this co-transplantation system, we established xenografts from 10 GC organoid lines. Importantly, the histopathological traits of parental tumors were preserved in xenografts, indicating that histological subtypes were determined cell autonomously rather than by the surrounding niche environments ( Figures 7C and S7A ). GC organoids included various histological subtypes of GC, such as signet ring cell carcinoma, providing valuable opportunities for investigating rare GCs in vivo.
The high proportion of Wnt-dependent GCs in the GTOL inspired us to examine the feasibility of a Wnt-targeting strategy on human GCs by in vivo administration of a Porcn-i. To this end, we treated xenografts of three Ri, one Wnt CA , and one WRi GC organoid with a Porcn-i ( Figure 7D ). Interestingly, Porcn-i treatment significantly reduced the tumor size of Ri GC grafts, but the therapeutic effect was not observed in Wnt CA and WRi GC organoids ( Figures 7E and 7F ). To validate that the Porcn-i specifically exerted this therapeutic effect through its Wnt-inhibitory function, we analyzed AXIN2 expression in xenografts. As expected, Porcn-i treatment did not alter AXIN2 expression in Wnt CA or WRi GC organoid tumors but significantly decreased its expression in Ri GC organoid grafts ( Figures 7G and 7H ). These results indicate that the nichederived Wnt signal served as a vital lifeline for Ri GCs and that the Wnt niche could be a targetable module for a subset of Wnt-dependent human GCs.
DISCUSSION
The pervasive histological and molecular heterogeneity across human GCs has hindered our access to the single patient-level connections between their genetic abnormalities and biological behaviors. To explore this relationship on an individualized basis, we generated a range of GC organoids that encompassed the histological, molecular, and phenotypic diversity of human GCs, including previously unestablished GS-GCs and hepatoid adenocarcinoma. The intensive characterization of GC organoids exposed novel associations between human GC genotypes and phenotypes, which were further cemented by prospective CRISPR engineering, xenotransplantation, and drug testing. Our GC organoid library not only provides a well-annotated resource for personalized human GC modeling and treatment, but it also highlights the power of the phenotype-based approach using patient-derived organoids in bridging the gap between the genetics and our current biological understandings of clinical GCs.
Of the four molecular subtypes of GC, the GS subtype has been considered the most ill-defined subgroup, both molecularly and functionally, owing to its low tumor purity and the lack of human cancer models. Capitalizing on the robustness of organoid technology, we successfully established four lines of GS-GC organoids characterized by DGC-like solid morphologies and minimal chromosomal alterations (Cancer Genome Atlas Research Network, 2014). GS-GC organoids exhibited chromosomal arm-level CN-LOHs encompassing known driver genes or fragile-site genes. In addition, all GS-GC organoids showed a CIMP-type methylation pattern, which has not been appreciated previously. These genetic and epigenetic modifications provided insights into the unique genetic basis of GS-GCs.
RHOA and CDH1 mutations frequently co-occur in DGCs, yet their functional roles in human gastric tumorigenesis have remained elusive. In this study, we found that CRISPR-based CDH1 KO organoids required inhibition of the RHOA-ROCK signal to sustain their growth as single cells, which might explain why these mutations preferentially co-occur. Recent literatures reported that RHOA mutations were not associated with the We have previously proposed that the cancer driver gene mutations allow the stem cells to thrive independently of their native niche constraint . Consistent with this notion, EGF, FGF10, epiregulin, and HGF were functional niche factors for gastric epithelial organoids, whereas the amplifications of RTK genes rendered the affected cells independent of these ligands. RTK-amplified or EREG-overexpressing GC organoids exhibited specific susceptibility to the corresponding RTK inhibitors, providing functional evidence for the effective genetics-based RTK targeting. Nonetheless, biological responses in GC organoids were not always genetically predictable. For example, KRAS mutations and PTEN mutations bypass ligand-dependent EGFR activation in colorectal cancers Matano et al., 2015) , but these mutations did not necessarily generate EF independency or Ei tolerability in GC organoids. In light of the recent co-clinical trial using patient-derived organoids (Vlachogiannis et al., 2018) , we envision that organoid-based assays will provide more practical strategies for patient stratification toward personalized medicine.
R-spondin is one of the principal niche factors for gastrointestinal stem cells and its engagement with LGR5 counteracts RNF43 and ZNRF3 mediated degradation of Frizzled receptors. Consistent with previous studies on the intestinal epithelium (Koo et al., 2012; Schwank et al., 2013) , concurrent RNF43 and ZNRF3 deletions were essential for the Ri phenotype in the human gastric epithelium. Nonetheless, previous genetic analyses rarely detected ZNRF3 gene alterations (Cancer Genome Atlas Research Network, 2014; Kakiuchi et al., 2014; Wang et al., 2014) . The existence of dominant-negative mutations in RNF43 partially explained this discrepancy. Alternatively, homozygous deletions and CpG island methylations of ZNRF3 induced Ri in cooperation with RNF43 mutations. Therefore, despite the high prevalence of RNF43 mutations, precise assessment of their biological impacts requires a thorough inspection of their mutational positions and the existence of concurrent ZNRF3 gene alterations.
The GTOL comprised additional Ri GCs that were devoid of RNF43 alterations. A forward-genetics approach revealed the enrichment of CDH1/TP53 compound mutations in these RNF43-intact Ri GCs. Although both CDH1 and TP53 were considered independent cancer driver genes in GCs, our results suggest that these mutations could collaborate to gain a cancer phenotype. Interestingly, the functional synergy was tissue specific, as CT-DKO did not confer Ri on human IM or colon organoids. This result was consistent with previous findings that tissue-specific CT-DKO mice developed gastric but not intestinal cancers (Shimada et al., 2012; Park et al., 2014) . Of note, CT-DKO mice also developed breast cancers (Derksen et al., 2006) , and future studies may prove whether breast cancer organoids with CT mutations gain Ri. Unlike RZ mutant GC organoids, CT mutant organoids showed R-spondin-mediated Frizzled stabilization, suggesting that their Ri phenotype was driven by an RNF43-independent mechanism. Previous reports proposed that CDH1 loss activates Wnt signaling by unleashing membrane-bound b-catenin, which, in turn, activates Wnt/b-catenin signaling (Gottardi et al., 2001; Orsulic et al., 1999) . Although CT-DKO organoids remained stringently dependent on exogenous Wnt-3A, they showed a higher level of Wnt signaling, suggesting that CT double loss imparted basal Wnt signaling activation which could render signal amplification by R-spondin dispensable. Further investigation is required to decipher the detailed molecular mechanisms of the CT mutation-mediated Ri phenotype.
Human GCs exhibited unique R-spondin independencies, while most of them remained dependent on Wnt ligands. This persistent dependency on Wnt ligands was a therapeutically actionable target for a subset of GCs. Using Porcn-i treatment, we demonstrated that Wnt targeting efficiently suppressed the tumorigenesis of Ri GCs. In contrast, Porcn-i treatment did not inhibit the growth of xenografts derived from WRi or Wnt CA GC organoids, which paralleled in vitro insensitivities to this compound. Clinical trials testing Porcn inhibitors for several types of cancers are currently underway (Lu et al., 2016) . Because few effective molecular targeting strategies are available for DGCs, Wnt targeting in combination with organoid-based drug testing may open a new therapeutic avenue for patients with this fatal disease.
In summary, we established a patient-derived GC organoid library that encompasses various histological and genetic subtypes and offers a biological access to human GCs. By combining a phenotype-based screening and CRISPRbased reverse-genetics approach, we present a new paradigm for investigating the functional roles of driver gene mutations in GCs.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Generation of gastric normal and tumor organoids Clinical samples used for organoid establishment and biological analyses were obtained from patients at Keio University Hospital with informed consent after the approval of the ethical committee. Detailed clinical information is provided in Table S1 . Healthy and GC specimens were collected by surgical resection, endoscopic biopsy, or ascites puncture. Organoids were established as previously reported (Bartfeld et al., 2015) , with additional modifications for each GC sample type. Normal colon organoid line was previously established (Sugimoto et al., 2018) . Surgical specimens were washed vigorously with phosphate-buffered saline (PBS) and minced into 1 mm 3 fragments using surgical scissors. The fragments were digested with Liberase TH (Roche) at 37 C for 30 min and undigested pellets were further treated with TrypLE Express (Thermo Fisher Scientific) at 37 C for 10 min. Prior to plating, collected epithelia were washed with PBS supplemented with 10% fetal bovine serum (FBS) to inactivate digestive enzymes. Ascites samples were centrifuged and washed 3 times with ice-cold PBS, and sedimented cells were used for organoid culture. Isolated gastric cells were embedded in Matrigel droplets and overlaid with the culture medium. The culture medium was prepared as previously described (Seino et al., 2018) , except for addition of FGF10. Advanced Dulbecco's Modified Eagle's Medium/F12 was supplemented with penicillin/streptomycin, 10 mM HEPES, 2 mM GlutaMAX, 1 3 B27 (Thermo Fisher Scientific), 10 nM gastrin I (Sigma), and 1 mM N-acetylcysteine (Wako, Japan) to prepare a basal culture medium. A complete medium was prepared by supplementing the basal culture medium with the following niche factors: 50 ng/ml mouse recombinant EGF (Thermo Fisher Scientific), 50 ng/ml human recombinant FGF10 (Peprotech), 100 ng/ml mouse recombinant noggin (Peprotech), 1 mg/ml human recombinant R-spondin1 (R&D), 25% Afamin-Wnt-3A serum-free conditioned medium (Mihara et al., 2016) , and 500 nM A83-01 (Tocris). Plated organoids were maintained in a CO 2 incubator with 5% CO 2 and 20% O 2 , and the media were changed every 3 or 4 days. For the enrichment of GC organoids, one-week treatment with 3 mM Nutlin-3 (Cayman Chemicals), culturing in the absence of Y-27632 (Wako) following complete single-cell dissociation, culturing in the absence of A83-01 and presence of TGF-b (10 ng/ml; R&D) and culturing in the absence of EGF and FGF10 were used. For the suppression of endogenous Wnt production, organoids were treated with 100 nM C59 (ShangHai Biochempartner). Once tumor-derived organoids were established, each niche factor was individually removed to determine the minimally essential niche conditions. When the organoids survived without a given niche factor for at least 1 month, the organoids were judged as being independent of the niche factor. When the removal of a niche factor partially inhibited organoid growth, we extended the observation period to 3 months and judged the niche factor to be dispensable when the organoid was surviving and expandable at that point. Established organoids were subjected to molecular analyses and cryopreserved as previously described (Seino et al., 2018) . For cryopreservation of the organoids, culture media was removed and added with 500 ml/well of recovery cell culture freezing medium (Thermo Fisher Sientific). Organoids and Matrigel were mechanically divided using 1,000 mL pipette and transfered into cryovials. Cryovials were placed into a freeze container, and incubated for 24 hr at À80 C. Frozen cryovials were then transferred to a liquid nitrogen storage tank.
Mice
All animal procedures were approved by the Keio University School of Medicine Animal Care Committee. Male NOD/Shi-scid, IL-2Rg null (NOG) mice were obtained from the Central Institute for Experimental Animals (CIEA, Japan) and housed under specific pathogen-free conditions.
METHOD DETAILS
Gene manipulation of gastric organoids For gene knockout using CRISPR-Cas9, gene specific single-guide RNAs (sgRNAs) were cloned into the pX330-U6-Chimeric_BB-CBh-hSpCas9 vector. KI of KRAS G12V was performed as previously described by co-introducing CRISPR vector into organoids with KRAS G12V donor vector. KO of TP53, CDH1, RHOA, CTNNA1, CTNNA2, CTNNA3 and RNF43 genes were performed by co-introducing each CRISPR vector into organoids with a GFP-puro expressing piggyBAC vector (PB513B-1, SBI), and organoids were subsequently treated with puromycin (2 mg/ml) to enrich organoids that have undergone successful plasmid delivery. CDH1, RHOA and CTNNA1 mutants were further enriched by complete single cell dissociation of the organoids followed by the culture without Y-27632 as mentioned in the main text. TP53 mutants were selected by 3 mM Nutlin-3. KRAS G12V mutants were selected by the EF-removed condition. As CTNNA2, CTNNA3 and RNF43 KO organoids could not be selected by culture conditions, puromycin-resistant single organoids were manually picked up. To obtain clonal KO organoids, single organoids were isolated and expanded. Successful gene KO by the introduction of biallelic frameshift mutations was confirmed by the TIDE (Brinkman et al., 2014) or Sanger sequencing using bacterially cloned DNA as previously described . Briefly, genomic DNA was extracted from engineered organoids, followed by PCR amplification of targeted loci. PCR products were directly analyzed, or cloned using TOPO-TA cloning kit (Thermo Fisher Scientific) and subsequently analyzed by Sanger sequencing. The results of the TIDE analyses are shown in Table S2 .
For conditional-gene overexpression experiments, RHOA WT or RHOA G62E cDNA was cloned into the XLone-GFP vector (Randolph et al., 2017) (Addgene#96930) by replacing the GFP cassette using KpnI and SpeI digestion sites. For RHOA FRET activity analysis, RHOA WT or RHOA G62E cDNAs were fused to the C terminus of synthesized VN173 and linker peptides, and further attached to the N terminus of mScarlet-i fused with PKN1-RHO binding domain, which was then cloned into the XLone vector. Vectors were electrotransferred into organoids as previously described and were selected with blasticidin (5 mg/ml) in experiments using XLone vectors or with hygromycin (200 mg/ml) in experiments using the PB-Tet-on vector. Gene expression was induced using 50-500 ng/ml of Doxycycline.
RHOA activation assay using FRET biosensor To investigate the RHOA-GTP loading capacity of mutant RHOA G62E , a doxycycline-inducible single chain FRET biosensor was synthesized based on a previously reported DORA-mScarlet-I-SGFP2 vector (Bindels et al., 2017) . When RHOA-GDP is converted to RHOA-GTP, a PKN1 moiety binds to RHOA-GTP, resulting in a high FRET state, which is detected as an increase in sensitized emission over VN173 ratio. To examine the FRET ratio contrast between the active and inactive states, synthesized constitutively active Q63L mutant and primary inactivated T19N mutant RhoA were used as positive and negative controls, respectively. 293T cells were transfected with 4 mg of the plasmid, and were grown under general growth culture conditions for overnight, followed by a culture with doxycycline (50 ng/ml) in a serum-free medium for 16 hr. Sequential images (donor excitation-donor emission (Donor), donor excitation-acceptor emission (FRET), acceptor excitation-acceptor emission (Acceptor)) were recorded using a confocal microscope (SP8, Leica). The donor (VN173) was excited at 488 nm, and collected using a 493-593 nm filter. The acceptor (mScarlet-I) was excited at 562 nm, and emission was collected by a 576-676nm filter. In order to extract the pure donor or acceptor emission from sensitized emission, background intensities were determined from cells expressing donor only and acceptor only using the same microscope settings of the measurements. The drawing of the regions of interest on random transfected cells and raw intensity measurement were carried out automatically using the ImageJ. FRET ratios were obtained by calculating background-subtracted FRET intensities divided by background-subtracted donor intensities in each regions of interest.
Time-Lapse Live Imaging
Time-lapse laser-scanning confocal fluorescence microscopy imaging of CDH1 KO organoids was performed using the Confocal Quantitative Image Cytometer CQ1 (Yokogawa Electric). We used 50 nM SiR-actin (CY-SC001, Cytoskeleton), a fluorogenic F-actin labeling chemical probe for live cells, for the visualization of F-actin. Cytoplasmic GFP was excited at 488 nm and collected using a 447/60 nm bandpass filter, and fluorophore silicon rhodamine-labeled F-actin was excited at 640 nm and collected using a 685/40 nm bandpass filter. After a Y-27632 wash out, z stack images were captured at 30-minute intervals for 3 days and reconstructed using the maximum-intensity projection method to make movies.
Molecular analyses for GC organoids DNA was extracted from organoids or blood with the QIAamp Blood Mini Kit (QIAGEN) and treated with RNase Cocktail (Ambion). The quality of DNA specimens was confirmed by agarose gel electrophoresis within the expected range of DNA fragmentation. Three micrograms of genomic DNA was fragmented for whole-exome sequencing analyses as previously described (Seino et al., 2018) . Paired-end libraries were prepared using the SureSelect Human All Exon V5 or V6 kit (Agilent) according to the manufacturer's instructions and were sequenced using Illumina HiSeq2500 (outsourced to Hokkaido System Science) or HiSeq4000 (outsourced to BGI JAPAN K.K.). Cleaned fastq files were mapped onto human reference genome version GRCh37 (hg19) using BWA. The generated reads were processed with the Genome Analysis Toolkit (GATK, version 1.6.13). Single-nucleotide variations (SNVs), insertions, and deletions were detected using GATK UnifiedGenotyper. Variants were annotated using SnpEff and filtered by removing those registered in SNV databases (dbSNP build 130 or lower), in the 1000 Genomes Project with a frequency of > 0.01, or in the Japanese SNP database (the Human Genetic Variation Database). When pairwise normal organoids or blood samples were available, variants were further filtered by altering their allele frequency (> 0.08). Additionally, we confirmed the variants and indels as SNPs that existed in more than 2 normal or blood samples included in GTOL and our previously reported organoid libraries (PTOL and CTOL) (Seino et al., 2018) . The list of detected SNV and indels after SNP-filtering is shown in Table S3 .
To assess genetic stability during passage and to dissect genetic heterogeneity in mixed-type GC organoids, we measured variant allele frequencies (VAFs) using GATK-detected variants with coverage R 100 which were selected before SNP filtering. For mixedtype GC organoids, GATK-detected variants were SNP-filtered and shown in Table S6 .
For copy number analysis, 500 ng of genomic DNA was applied to the CGH/SNP microarray (CytoScan HD, Thermo Fisher Scientific), according to the manufacturer's instructions. We used ''apt-copynumber-cyto-ssa'' in the Affymetrix Power Tools (version 1.19.0) with normal-diploid-normalization option to obtain probe-level copy number and the allele difference. All parameters were set according to recommendation in user manual. Segmentation analysis was performed with ''segmentCGH'' function in the R/Bioconductor package ''rCGH'' (version 1.8.1) using log 2 ratio values of CN-probes. The mean log 2 ratio of segments were visualized after centering the median copy number of each sample. GISTIC2.0 was used to identify recurrent copy number alterations and calculate gene-level copy number. We detected a focal amplification at the tail end of chromosome 14 in all samples, even in normal organoids. We judged this amplification event as a platform-specific artifact, and excluded all probes within the genomic range of chr14:106000000-107349540 from GISTIC2.0 analysis. Gene-level Log2Ratio was thresholded at 1 and À1 to detect gene amplification and homozygous deletion.
For methylation analysis, 500 ng of genomic DNA was subjected to bisulfite conversion and applied to an Infinium MethylationEPIC microarray (Illumina) according to the manufacturer's instructions. We used R/Bioconductor package ''wateRmelon'' (version 1.20.3) to process raw methylation data. Raw methylation data of 35 GC organoids and 15 normal/normal-like organoids were normalized by the dasen function, and outliers were removed by the pfilter function. Probes targeting SNPs and genes located on sex chromosomes were filtered out before analysis. We used K-means clustering (K=3) to determine GC organoid subtypes (CIMP + , CIMP -and normal/ normal-like). Principal component analysis (PCA) was performed using probes exhibiting large variance (M-value variance > 4). Gene methylation level was obtained by selecting a probe with the largest negative correlation to the expression in probes mapped to the same gene loci (from 1.5 kbp upstream of the transcription start site to the transcription end site). Methylation levels of top 1,000 genes exhibiting the largest variance across GC organoids were visualized in Figure 1D . Hierarchical clustering was performed with ''hclust'' function in R using Euclidean distance and ward.D2 linkage metrics. GC33 was excluded from all statistical analyses as it largely shared molecular characteristics with GC34, which was derived from the same patient as GC33.
Genetic screening for the Ri phenotype A gene was regarded as ''mutated'' when it had a homozygous mutation and the mutation resulted in a non-synonymous substitution or splice-site disruption. As an exception, heterozygous mutations in KRAS, RHOA and PIK3CA with known oncogenic impact were regarded as ''mutated.'' Mutated genes identified in less than 2 GC organoids and genes with mutation frequencies less than 10 /Mbp were filtered out. Mutation frequency of each gene in Ri GC organoids was compared to that in WRd GC organoids by Fisher's exact test. 314 genes and all combinations of 2 genes from the 314 genes were examined. GC33 was excluded from the genetic screening due to the reason mentioned above. Mutated genes enriched in Ri GC organoids are shown in Table S4 .
Gene Expression Microarray Analysis
Organoids were cultured from single cells for 5 days in the complete culture condition. RNA was extracted from organoids using the RNeasy Plus Mini Kit (QIAGEN). RNA quality was evaluated based on the RNA Integrity Number (RIN) value determined in RNA6000 assays (Agilent). Only specimens with RIN > 7.0 were used in this study. Gene expression profiling was performed using the PrimeView Human Gene Expression Array (Affymetrix) according to the manufacturer's instructions. Raw expression data of 36 GC organoids and 18 normal/normal-like organoids were normalized using the rma function in the R/Bioconductor package with PBS by centrifuging, and the cell palettes were suspended in PBS containing 0.1% BSA and a phycoerythrin (PE)-conjugated goat anti-human IgG Fcg fragment-specific antibody and incubated for 15 min at room temperature. The cells were washed again twice with PBS, suspended in PBS containing DAPI (564907, BD Biosciences, 1:1000), and analyzed using a cell sorter (SH800, Sony). For control, cells were labeled only with the secondary antibody.
Xenografting of GC organoids
Prior to the assay, the organoids were labeled by electroporation with a GFP-puro PiggyBac vector (System Biosciences) as previously described . In parallel, we prepared fibroblasts from a HIO (kindly provided from James Wells, Cincinnati Children's Hospital). After the isolation by manual picking, HIOFs were expanded in the HFDM-1 medium (Cell Science & Technology) supplemented with 5% FBS and 1% penicillin/streptomycin, cryopreserved at early passages, and recovered 1 week before the transplantation. For xenografting, GC organoids were isoloated from Matrigel using Cell Recovery Solution (BD Biosciences) and physically dissociated into cell clusters by brief pipetting. For each transplantation, GC cell clusters (equivalent to 1 3 10 5 cells) and detached HIOFs (2 3 10 5 cells) were re-suspended in 10 mL of cold Matrigel and injected into a kidney subcapsule of a NOG mouse (8-12 weeks old, male). Each GC organoid line was transplanted into 4 independent NOG mice. At 2 months post-transplantation, mice were euthanized and the grafts were isolated. Tumor sizes were measured as the areas of GFP fluorescence (Nikon Multi-zoom microscopy, LuminaVision software). The grafts were fixed for subsequent histological analyses. For Porcn-i-treatment experiments, tumor-bearing mice were randomized before treatment and treated with C59 (50 mg/kg, administered daily by oral gavage) as demonstrated in Figure 7D .
Immunohistochemistry and in situ hybridization Isolated xenografts were immediately fixed with 4% paraformaldehyde. The standard protocols for sectioning paraffin-embedded tissues and H&E staining were used. Whole-mount immunofluorescent staining of organoids was performed as previously described (Seino et al., 2018) . For immunostaining, rat anti-integrin-a6 (313601, Biolegend, 1:100), rabbit anti-a-catenin (CTNNA1) (C2081, Sigma-Aldrich, 1:2000), rabbit anti-Ki67 (ab16667, abcam, 1:100), mouse anti-CDX2 (MU392, BioGenex, 1:300) and goat anti-E-cadherin (AF748, R&D, 1:100) antibodies were used, with subsequent labeling by Alexa Fluor 488-, 568-or 647-conjugated anti-rat, -goat, -rabbit or -mouse antibodies (Thermo Fisher Scientific). Alexa Fluor 647-phalloidin (A22287, Thermo Fisher Scientific) was used for the visualization of F-actin. Nuclei were counterstained with Hoechst 33342 (Thermo Fisher Scientific). For in situ hybridization, we used an RNAscope 2.5 HD Kit (Advanced Cell Diagnostics), according to the manufacturer's instructions. Probes for AXIN2 and EBER1 were designed by Advanced Cell Diagnostics. PPIB and DapB genes were used as positive and negative controls, respectively. Images were captured using a BZ-X710 digital microscope (Keyence) or a confocal microscope (SP8, Leica).
QUANTIFICATION AND STATISTICAL ANALYSIS
Pairwise analyses for tumor volumes and gene expression values were performed using unpaired two-tailed Welch's t test. For further statistical details, refer to each figure legend.
DATA AND SOFTWARE AVAILABILITY
The accession number for the gene expression microarray data reported in this paper is GEO: GSE112369.
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